Active, not recruitingPhase 3NCT07406854
A Phase 3, Multicenter, Randomized, Double-Masked, Sham-Controlled Clinical Trial for Leber's Hereditary Optic Neuropathy (LHON) Associated With ND4 Mutation
Studying Leber hereditary optic neuropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Wuhan Neurophth Biotechnology Limited Company
- Intervention
- rAAV2-ND4(genetic)
- Enrollment
- 95 enrolled
- Eligibility
- 12-75 years · All sexes
- Timeline
- 2024 – 2030
Study locations (1)
- Beijing Tongren Hospital, Capital Medical University, Beijing, Beijing Municipality, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07406854 on ClinicalTrials.govOther trials for Leber hereditary optic neuropathy
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT05293626Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated With ND4 MutationsNeurophth Therapeutics Inc
- RECRUITINGNANCT06682819Metabolomics Analysis According to the Retinal Nerve Fiber Layer in Patients With NOHL Mutations (MétabOCT)Hôpital Necker-Enfants Malades
- ENROLLING BY INVITATIONNCT06376279Genetic Diagnosis in Inborn Errors of MetabolismRegion Stockholm